|Day Low/High||240.63 / 243.09|
|52 Wk Low/High||210.28 / 276.69|
Traders could go long at current levels risking below $240 for now.
Let's review this Archegos drama and some lessons from this fickle market.
The fact is that even if there is some compromise, the next fiscal stimulus package will be closer to $1.9 trillion than $600 billion.
The fears of what would happen from Democratic wins in Georgia's race failed to pan out, aside from tech taking a few hits. Here's what's happening instead and why.
As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.
From Amazon to Zoom, here are my prognostications and best ideas for the new year.
Let's compare several dividend increases in time for the holidays -- and see who wins the 'derby.'
These names are displaying technical deterioration.
With four consecutive flat quarterly dividends, this pharmaceutical name could be on the verge of another hefty raise.
The average declined in October, but it was less than that hit took by the major indexes.
The 'work from home' or 'economic lockdown' trade is close to being back on.
Successful tests of a rising 200-day moving average line can be great entry points for longs.
How September markets digest August ahead of momentous events will be far more important to uptrend maintenance than how August closed.
Apple's weight in the (price-weighted) Dow Jones Industrial Average, effective this morning, will be reduced from 12% to 3% -- based on the company's 4-1 stock split. In response to that split, Amgen , Honeywell , and Salesforce are being added to t...
September, not October, is historically the weakest month of the year for equity markets, though October has had more high profile collapses.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Let's check the charts as this biotech replaces Pfizer on the DJIA.
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
What I see: This stock responds well to economic recovery.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.
I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.
The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.